Catalyst Capital Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-88
| Closed | -$15.5K | – | 373 |
|
|
2025
Q4 | $15.5K | Buy |
88
+19
| +28% | +$3.1K | ﹤0.01% | 354 |
|
|
2025
Q3 | $9.67K | Sell |
69
-20
| -22% | -$2.7K | ﹤0.01% | 443 |
|
|
2025
Q2 | $11.2K | Sell |
89
-25
| -22% | -$3.12K | ﹤0.01% | 450 |
|
|
2025
Q1 | $15.6K | Hold |
114
| – | – | ﹤0.01% | 416 |
|
|
2024
Q4 | $17.4K | Sell |
114
-485
| -81% | -$81.8K | ﹤0.01% | 448 |
|
|
2024
Q3 | $116K | Buy |
599
+457
| +322% | +$95.6K | ﹤0.01% | 264 |
|
|
2024
Q2 | $32.9K | Buy |
142
+4
| +3% | +$869 | ﹤0.01% | 280 |
|
|
2024
Q1 | $29.8K | Buy |
+138
| New | +$32.3K | ﹤0.01% | 287 |
|
|
2023
Q4 | – | Sell |
-107
| Closed | -$27.5K | – | 382 |
|
|
2023
Q3 | $27.5K | Buy |
107
+27
| +34% | +$7.22K | ﹤0.01% | 292 |
|
|
2023
Q2 | $22.8K | Sell |
80
-4
| -5% | -$1.19K | ﹤0.01% | 306 |
|
|
2023
Q1 | $23.4K | Sell |
84
-28
| -25% | -$7.75K | ﹤0.01% | 290 |
|
|
2022
Q4 | $31K | Sell |
112
-4
| -3% | -$1.13K | ﹤0.01% | 277 |
|
|
2022
Q3 | $31K | Sell |
116
-1
| -0.9% | -$212 | ﹤0.01% | 288 |
|
|
2022
Q2 | $24K | Buy |
117
+16
| +16% | +$3.27K | ﹤0.01% | 313 |
|
|
2022
Q1 | $21K | Buy |
101
+19
| +23% | +$4.13K | ﹤0.01% | 377 |
|
|
2021
Q4 | $20K | Sell |
82
-8
| -9% | -$2.06K | ﹤0.01% | 359 |
|
|
2021
Q3 | $25K | Sell |
90
-3
| -3% | -$983 | ﹤0.01% | 330 |
|
|
2021
Q2 | $32K | Buy |
93
+3
| +3% | +$909 | ﹤0.01% | 334 |
|
|
2021
Q1 | $25K | Sell |
90
-638
| -88% | -$172K | ﹤0.01% | 310 |
|
|
2020
Q4 | $178K | Sell |
728
-362
| -33% | -$93.4K | 0.01% | 242 |
|
|
2020
Q3 | $309K | Sell |
1,090
-195
| -15% | -$54.4K | 0.02% | 201 |
|
|
2020
Q2 | $344K | Hold |
1,285
| – | – | 0.02% | 204 |
|
|
2020
Q1 | $407K | Sell |
1,285
-265
| -17% | -$80.4K | 0.02% | 156 |
|
|
2019
Q4 | $460K | Buy |
+1,550
| New | +$430K | 0.01% | 194 |
|
|
2019
Q2 | – | Sell |
-3,750
| Closed | -$886K | – | 420 |
|
|
2019
Q1 | $886K | Buy |
+3,750
| New | +$1.18M | 0.03% | 135 |
|
|
2018
Q4 | – | Sell |
-2,100
| Closed | -$742K | – | 424 |
|
|
2018
Q3 | $742K | Buy |
+2,100
| New | +$723K | 0.02% | 196 |
|
|
2016
Q4 | – | Sell |
-353
| Closed | -$111K | – | 415 |
|
|
2016
Q3 | $111K | Sell |
353
-11,050
| -97% | -$3.27M | 0.01% | 270 |
|
|
2016
Q2 | $2.76M | Sell |
11,403
-16,520
| -59% | -$4.35M | 0.51% | 73 |
|
|
2016
Q1 | $7.27M | Sell |
27,923
-239
| -0.8% | -$63.1K | 1.22% | 23 |
|
|
2015
Q4 | $8.63M | Buy |
28,162
+27,615
| +5,048% | +$7.94M | 1.25% | 17 |
|
|
2015
Q3 | $160K | Buy |
547
+447
| +447% | +$148K | 0.02% | 295 |
|
|
2015
Q2 | $40K | Hold |
100
| – | – | ﹤0.01% | 372 |
|
|
2015
Q1 | $42K | Hold |
100
| – | – | ﹤0.01% | 339 |
|
|
2014
Q4 | $34K | Buy |
+100
| New | +$32.4K | ﹤0.01% | 356 |
|
|
2014
Q2 | – | Sell |
-212
| Closed | -$65K | – | 352 |
|
|
2014
Q1 | $65K | Buy |
+212
| New | +$67.3K | 0.01% | 296 |
|
Other funds holding BIIB
VCM
VPM
Catalyst Capital Advisors's BIIB Position: Q1 2026 in Review
Catalyst Capital Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 88 shares — an estimated $15.5K sold.
Catalyst Capital Advisors first reported a position in BIIB in Q1 2014 and held it in 35 quarters. The position peaked at $8.63M in Q4 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Catalyst Capital Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- Catalyst Capital Advisors sold 88 Biogen shares in Q1 2026, an estimated $15.5K.
- Catalyst Capital Advisors first reported a position in Biogen in Q1 2014 and held it in 35 quarters.
- Catalyst Capital Advisors's Biogen position peaked at $8.63M in Q4 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Catalyst Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.